<![CDATA[Hypertension]]> https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/diseases-conditions/hypertension Fri, 01 May 2026 20:34:17 +0000 Zend_Feed http://blogs.law.harvard.edu/tech/rss <![CDATA[Resistant Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]> https://www.leadingmarketresearch.com/resistant-hypertension-drugs-in-development-by-stages-target-moa-roa-mo

Summary

Resistant Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Resistant Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Resistant Hypertension, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databas...

$2,000.00
]]> Wed, 13 Jul 2022 12:37:01 +0000 <![CDATA[Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]> https://www.leadingmarketresearch.com/pulmonary-arterial-hypertension-drugs-in-development-by-stages-target-moa

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Drugs In Development, 2022, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pulmonary Arter...

$2,500.00
]]> Fri, 17 Jun 2022 15:11:14 +0000 <![CDATA[Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]> https://www.leadingmarketresearch.com/ocular-hypertension-drugs-in-development-by-stages-target-moa-roa-molec

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, me...

$2,000.00
]]> Fri, 03 Jun 2022 13:17:15 +0000 <![CDATA[Ocular Hypertension - Pipeline Insight, 2021]]> https://www.leadingmarketresearch.com/ocular-hypertension-pipeline-insight-2021 DelveInsight’s, “Ocular Hypertension - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Ocular Hypertension Understanding Ocular Hypertension: Overview Ocular hypertension is elevated intraocular pressure (IOP) without any evidence of glaucomatous optic neuropathy. It is not a disease; however, increased eye pressure is the most important risk factor in the development of open angle glaucoma. Ocular hypertension can be categorized similarly to glaucoma with various possible mechanisms of etiology associated with an open or closed (or narrow) angle and associated primary or secondary causes. Ocular hypertension has no noticeable signs or symptoms. If the pressure is too high ...
$1,500.00
]]> Fri, 19 Mar 2021 14:59:26 +0000 <![CDATA[Pulmonary Arterial Hypertension (PAH) – Pipeline Insight, 2020]]> https://www.leadingmarketresearch.com/pulmonary-arterial-hypertension-pah-pipeline-insight-2020 DelveInsight’s, “Pulmonary Arterial Hypertension (PAH) – Pipeline Insight, 2020,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Pulmonary Arterial Hypertension Understanding Pulmonary Arterial Hypertension: Overview Pulmonary arterial hypertension is a progressive disorder characterized by abnormally high blood pressure (hypertension) in the pulmonary artery, the blood vessel that carries blood from the heart to the lungs. Pulmonary arterial hypertension is one form of a broader condition known as pulmonary hypertension. Pulmonary hypertension occurs when most of the very small arteries throughout the lungs narrow in diameter, which increases the resistance to blood flow through the...
$2,500.00
]]> Thu, 15 Oct 2020 14:02:56 +0000 <![CDATA[Pulmonary Arterial Hypertension - Pipeline Review, H1 2020]]> https://www.leadingmarketresearch.com/pulmonary-arterial-hypertension-pipeline-review-h1-2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2020, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pulmonary Arterial ...

$2,000.00
]]> Thu, 07 May 2020 13:39:47 +0000 <![CDATA[Ocular Hypertension - Pipeline Review, H2 2019]]> https://www.leadingmarketresearch.com/ocular-hypertension-pipeline-review-h2-2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H2 2019, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechan...

$2,000.00
]]> Wed, 11 Dec 2019 11:38:48 +0000 <![CDATA[Pulmonary Arterial Hypertension - Pipeline Review, H2 2019]]> https://www.leadingmarketresearch.com/pulmonary-arterial-hypertension-pipeline-review-h2-2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2019, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pulmonary Arterial ...

$2,000.00
]]> Wed, 11 Dec 2019 11:38:48 +0000 <![CDATA[Pulmonary Arterial Hypertension - Pipeline Review, H1 2019]]> https://www.leadingmarketresearch.com/pulmonary-arterial-hypertension-pipeline-review-h1-2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2019, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Pulmonary Arterial ...

$2,000.00
]]> Tue, 26 Mar 2019 12:29:57 +0000 <![CDATA[Global Pulmonary Arterial Hypertension Market Research Report 2018]]> https://www.leadingmarketresearch.com/global-pulmonary-arterial-hypertension-market-research-report-2018 Pulmonary Arterial Hypertension Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the Pulmonary Arterial Hypertension basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report includes six parts, dealing with: 1.) Basic Information; 2.) Asia Pulmonary Arterial Hypertension Market; 3.) North American Pulmonary Arterial Hypertension Market; 4.) Europe...
$2,850.00
]]> Thu, 06 Dec 2018 13:11:29 +0000 <![CDATA[Systolic Hypertension Global Clinical Trials Review, H2, 2018]]> https://www.leadingmarketresearch.com/systolic-hypertension-global-clinical-trials-review-h2-2018

Summary

GlobalData's clinical trial report, “Systolic Hypertension Global Clinical Trials Review, H2, 2018" provides an overview of Systolic Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Systolic Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies t...

$2,500.00
]]> Wed, 17 Oct 2018 16:06:20 +0000 <![CDATA[Hypertension - Pipeline Review, H1 2018]]> https://www.leadingmarketresearch.com/hypertension-pipeline-review-h1-2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2018, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2018, provides comprehensive information on the therapeutic...

$2,000.00
]]> Mon, 03 Sep 2018 14:10:02 +0000 <![CDATA[Hypertension Drugs Industry Forecasts - China Focus]]> https://www.leadingmarketresearch.com/hypertension-drugs-industry-forecasts-china-focus This study focuses on China’s Hypertension Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovat...
$1,800.00
]]> Wed, 09 May 2018 11:25:43 +0000 <![CDATA[Hypertension Drugs Companies in China]]> https://www.leadingmarketresearch.com/hypertension-drugs-companies-in-china-531 This study focuses on China’s Hypertension Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is sufferi...
$1,800.00
]]> Wed, 09 May 2018 11:25:43 +0000 <![CDATA[Hypertension Drugs Markets in China]]> https://www.leadingmarketresearch.com/hypertension-drugs-markets-in-china-32 China's demand for Hypertension Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are con...
$4,000.00
]]> Wed, 09 May 2018 11:25:43 +0000 <![CDATA[Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market]]> https://www.leadingmarketresearch.com/global-respiratory-complications-therapeutics-market-to-2022-innovative-p

Summary

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function. The causes of respiratory disorders vary significantly between indications, with potential causes including infection, vascular damage or dysfunction, aging, environmental stressors such as pollution, and genetic predisposition.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that treat the disease symptoms rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in cystic fibrosis (CF), where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The chronic obstructive pulmonary disease (COPD) and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators a...

$4,995.00
]]> Fri, 28 Apr 2017 10:35:57 +0000 <![CDATA[Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline]]> https://www.leadingmarketresearch.com/anti-hypertensive-therapeutics-in-asia-pacific-markets-to-2022-increasing

Summary

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment

The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin co...

$4,995.00
]]> Fri, 28 Apr 2017 10:35:57 +0000 <![CDATA[Resistant Hypertension - Pipeline Review, H2 2016]]> https://www.leadingmarketresearch.com/resistant-hypertension-pipeline-review-h2-2016

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Resistant Hypertension Overview 6
Pipeline Products for Resistant Hypertension - Overview 7
Resistant Hypertension - Therapeutics under Development by Companies 8
Resistant Hypertension - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Resistant Hypertension - Products under Development by Companies 11
Resistant Hypertension - Companies Involved in Therapeutics Development 12
Bayer AG 12
Novartis AG 13
Sarfez Pharmaceuticals Inc 14
PhaseBio Pharmaceuticals Inc 15
Zumbro Discovery Inc 16
Resistant Hypertension - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BAY-1636183 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LHW-090 - Drug Prof...

$2,000.00
]]> Fri, 07 Apr 2017 13:51:23 +0000 <![CDATA[Ocular Hypertension Global Clinical Trials Review, H2, 2016]]> https://www.leadingmarketresearch.com/ocular-hypertension-global-clinical-trials-review-h2-2016

Summary

GlobalData's clinical trial report, “Ocular Hypertension Global Clinical Trials Review, H2, 2016" provides an overview of Ocular Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Ocular Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain...

$2,500.00
]]> Wed, 11 Jan 2017 12:42:31 +0000 <![CDATA[Epiomic Epidemiology Series: Hypertension Forecast in 12 Major Markets 2016-2026]]> https://www.leadingmarketresearch.com/epiomic-epidemiology-series-hypertension-forecast-in-12-major-markets-2016 Hypertension (high blood pressure) is a common condition in which the force of the blood against the artery walls is high enough that it may eventually cause serious health problems. These health problems include heart attack, stroke, chronic kidney disease and heart failure. This report provides the current prevalent population for Hypertension across 12 Major Markets (USA, Canada, France, Germany, Russian Federation, Italy, Spain, UK, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Hypertension have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities for Hypertension include: ...
$6,400.00
]]> Wed, 30 Nov 2016 13:10:00 +0000 <![CDATA[OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast to 2024]]> https://www.leadingmarketresearch.com/opportunityanalyzer-pulmonary-arterial-hypertension-opportunity-analysis GlobalData estimates the 2014 sales for pulmonary arterial hypertension (PAH) at approximately $3.45 billion across the 7MM covered in this report, which include the US, 5EU and Japan. The market will grow moderately at a CAGR of 3.20% during the 10-year forecast period, generating sales of approximately $4.75 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 3.70% and generating around 75% of global sales in 2024. The major drivers for this growth across the 7MM will be the launch of Actelion’s Uptravi and the increased use of double and triple combination therapy....
$10,995.00
]]> Mon, 10 Oct 2016 12:19:19 +0000 <![CDATA[Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2016]]> https://www.leadingmarketresearch.com/pulmonary-arterial-hypertension-global-clinical-trials-review-h2-2016

Summary

GlobalData's clinical trial report, “Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2016" provides an overview of Pulmonary Arterial Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Arterial Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an ...

$2,500.00
]]> Thu, 15 Sep 2016 20:23:57 +0000 <![CDATA[Idiopathic Pulmonary Hypertension Global Clinical Trials Review, H2, 2016]]> https://www.leadingmarketresearch.com/idiopathic-pulmonary-hypertension-global-clinical-trials-review-h2-2016

Summary

GlobalData's clinical trial report, “Idiopathic Pulmonary Hypertension Global Clinical Trials Review, H2, 2016" provides an overview of Idiopathic Pulmonary Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to crea...

$2,500.00
]]> Thu, 15 Sep 2016 20:23:57 +0000 <![CDATA[Systolic Hypertension Global Clinical Trials Review, H2, 2016]]> https://www.leadingmarketresearch.com/systolic-hypertension-global-clinical-trials-review-h2-2016

Summary

GlobalData's clinical trial report, “Systolic Hypertension Global Clinical Trials Review, H2, 2016" provides an overview of Systolic Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Systolic Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies t...

$2,500.00
]]> Thu, 15 Sep 2016 20:23:57 +0000 <![CDATA[Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2016]]> https://www.leadingmarketresearch.com/chronic-thromboembolic-pulmonary-hypertension-global-clinical-trials-review-437

Summary

GlobalData's clinical trial report, “Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2016" provides an overview of Chronic Thromboembolic Pulmonary Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Thromboembolic Pulmonary Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision m...

$2,500.00
]]> Thu, 15 Sep 2016 20:23:57 +0000